Table 4.
Best tumor response according to RECIST
| Sur + Doc 75 mg/m2 | Sur + Doc 56 mg/m2 | Sur + Gem 1,250 mg/m2 | Total | |
|---|---|---|---|---|
| Evaluable for responsea | ||||
| No. of assessable patients | 5 | 6 | 5 | 16 |
| Progressive disease | 0 | 3 | 2 | 5 |
| Partial response (PR) | 1 | 1 | 0 | 2 |
| Time to PR (mo) | 6 | 3 | NA | NA |
| Duration of PR (mo) | 2.3 | 4.7 | NA | NA |
| Stable disease (SD) | 4 | 2 | 3 | 9 |
| Evaluable for time to progression and overall survivala | ||||
| Assessable patients | 6 | 6 | 6 | 18 |
| Median time to progression in months | 3.5 | 3.5 | 4.0 | 3.7 95% CI (2.5,5.4) |
| Median overall survival in months | 7.9 | 11.5 | 5.6 | 9.3 95% CI (4.2,13.5) |
a
Sixteen of 18 patients completed ≥2 cycles and were evaluable for response. All 18 patients were evaluable for time to progression and overall survival